Stocks
Silence Therapeutics plcSLN
NASDAQHealthcareBiotechnology$19.67
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing RNAi therapeutics targeting diseases with high unmet need, including cardiovascular and rare conditions. Its lead programs focus on silencing genes involved in lipid metabolism, with a pipeline that has attracted partnership interest from larger pharmaceutical firms. Investors track the stock for its late-stage data readouts and potential commercial partnerships.
52W Range: $4.19-$19.69
Congressional Interest in Silence Therapeutics plc (SLN)
No congressional trades have been disclosed for Silence Therapeutics plc (SLN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading SLN?
No congressional trades found for this stock.